A maxed-out liver: A case of acute-on-chronic liver failure

Seminars in Liver Disease

Volumn 31, Issue 4, 2011, Pages 420-426

  Im, Gene Y ^a   Kazi, Sofia ^a   Thung, Swan N ^a   Perumalswami, Ponni V ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

acute on chronic liver failure; Drug induced liver injury; glutathione; hepatitis; liver transplantation

Indexed keywords

CYSTEINE; D RIBOSE L CYSTEINE; MAXONE; UNCLASSIFIED DRUG;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; ASCITES; CASE REPORT; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENOTYPE; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER TRANSPLANTATION; MALE; PATHOLOGY; PATIENT REFERRAL; PRIORITY JOURNAL;

CYSTEINE; DIAGNOSIS, DIFFERENTIAL; DRUG-INDUCED LIVER INJURY; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; THIAZOLIDINES;

EID: 84455189493     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1297930     Document Type: Article

References (56)

1. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010 138 7 2246-2259
2. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002 22 2 145-155 (Pubitemid 34496468)
3. Bahirwani R, Shaked O, Bewtra M, Forde K, Reddy K R. Acute-on-chronic liver failure before liver transplantation: impact on posttransplant outcomes. Transplantation 2011 92 8 952-957
4. Ohnishi H, Sugihara J, Moriwaki H, Muto Y. [Acute-on-chronic liver failure]. Ryoikibetsu Shokogun Shirizu 1995 7 217-219
5. Escorsell Mañosa A, Mas Ordeig A. [Acute-on-chronic liver failure]. Gastroenterol Hepatol 2010 33 2 126-134
6. Graziadei I W. The clinical challenges of acute on chronic liver failure. Liver Int 2011 31 Suppl 3 24-26
7. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010 52 4 605-613
8. Garcia-Tsao G, Parikh C R., Viola A. Acute kidney injury in cirrhosis. Hepatology 2008 48 6 2064-2077
9. Borzio M, Salerno F, Piantoni L et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001 33 1 41-48 (Pubitemid 32186174)
10. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008 28 1 26-42 (Pubitemid 351326531)
11. Suriawinata A A., Thung S N. Chronic liver disorders. In: Suriawinata A A. Thung S N. eds. Liver Pathology: An Atlas and Concise Guide. New York, NY Demos Medical Publishing 2011 73-123
12. Girelli D, Pasino M, Goodnough J B. et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009 51 5 845-852
13. Hajdu C H., Lefkowitch J H. Adult polyglucosan body disease: a rare presentation with chronic liver disease and ground-glass hepatocellular inclusions. Semin Liver Dis 2011 31 2 223-229
14. Jurkowska H, Uchacz T, Roberts J, Wrñbel M. Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation. Amino Acids 2011 41 1 131-139
15. Oz H S., Chen T S., Nagasawa H. Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Transl Res 2007 150 2 122-129 (Pubitemid 47081449)
16. Rathbun W B., Killen C E., Holleschau A M., Nagasawa H T. Maintenance of hepatic glutathione homeostasis and prevention of acetaminophen-induced cataract in mice by L-cysteine prodrugs. Biochem Pharmacol 1996 51 9 1111-1116 (Pubitemid 26130401)
17. Lucas A M., Hennig G, Dominick P K., Whiteley H E., Roberts J C., Cohen S D. Ribose cysteine protects against acetaminophen-induced hepatic and renal toxicity. Toxicol Pathol 2000 28 5 697-704
18. Slitt A M., Dominick P K., Roberts J C., Cohen S D. Effect of ribose cysteine pretreatment on hepatic and renal acetaminophen metabolite formation and glutathione depletion. Basic Clin Pharmacol Toxicol 2005 96 6 487-494 (Pubitemid 40835705)
19. Roberts J C., Nagasawa H T., Zera R T., Fricke R F., Goon D J. Prodrugs of L-cysteine as protective agents against acetaminophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(polyacetoxyalkyl)thiazolidine-4(R)-carboxylic acids. J Med Chem 1987 30 10 1891-1896 (Pubitemid 18020922)
20. Crankshaw D L., Berkeley L I., Cohen J F., Shirota F N., Nagasawa H T. Double-prodrugs of L-cysteine: differential protection against acetaminophen-induced hepatotoxicity in mice. J Biochem Mol Toxicol 2002 16 5 235-244 (Pubitemid 35460436)
21. Roberts J C., Koch K E., Detrick S R., Warters R L., Lubec G. Thiazolidine prodrugs of cysteamine and cysteine as radioprotective agents. Radiat Res 1995 143 2 203-213
22. Warters R L., Roberts J C., Wilmore B H., Kelley L L. Modulation of radiation-induced apoptosis by thiolamines. Int J Radiat Biol 1997 72 4 439-448 (Pubitemid 27444519)
23. Waldren C A., Vannais D B., Ueno A M. A role for long-lived radicals (LLR) in radiation-induced mutation and persistent chromosomal instability: counteraction by ascorbate and RibCys but not DMSO. Mutat Res 2004 551 1-2 255-265 (Pubitemid 38833513)
24. Lenarczyk M, Ueno A, Vannais D B. et al. The pro-drug RibCys decreases the mutagenicity of high-LET radiation in cultured mammalian cells. Radiat Res 2003 160 5 579-583 (Pubitemid 38055206)
25. Anderson M E., Luo J L. Glutathione therapy: from prodrugs to genes. Semin Liver Dis 1998 18 4 415-424 (Pubitemid 29011044)
26. Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 2010 51 1 246-254
27. Yang R, Miki K, He X, Killeen M E., Fink M P. Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity. Crit Care 2009 13 2 R55
28. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007 47 513-539
29. Uetrecht J P. New concepts in immunology relevant to idiosyncratic drug reactions: the danger hypothesis and innate immune system. Chem Res Toxicol 1999 12 5 387-395 (Pubitemid 29352401)
30. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005 4 6 489-499 (Pubitemid 40861991)
31. Aithal G P., Ramsay L, Daly A K. et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004 39 5 1430-1440 (Pubitemid 38569066)
32. Ho R H., Kim R B. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005 78 3 260-277 (Pubitemid 41254111)
33. Pauli-Magnus C, Meier P J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006 44 4 778-787 (Pubitemid 46489540)
34. Zimmerman H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia Lippincott Williams & Wilkins 1999
35. Lewis J H. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 2002 1 2 159-172
36. Russo M W., Watkins P B. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology 2004 126 5 1477-1480 (Pubitemid 38552811)
37. Wong W M., Wu P C., Yuen M F. et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000 31 1 201-206
38. Lee B H., Koh W J., Choi M S. et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005 127 4 1304-1311 (Pubitemid 46224295)
39. Patel P A., Voigt M D. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002 97 5 1198-1203 (Pubitemid 34478122)
40. Ungo J R., Jones D, Ashkin D et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998 157 6 Pt 1 1871-1876
41. Eisenberg D M., Davis R B., Ettner S L. et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998 280 18 1569-1575 (Pubitemid 28520643)
42. Eisenberg D M., Kessler R C., Foster C, Norlock F E., Calkins D R., Delbanco T L. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993 328 4 246-252 (Pubitemid 23035311)
43. Graham R E., Gandhi T K., Borus J et al. Risk of concurrent use of prescription drugs with herbal and dietary supplements in ambulatory care. In: Henriksen K Battles J B. Keyes M A. Grady ML eds. Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 4: Technology and Medication Safety). Rockville, MD Agency for Healthcare Research and Quality (US) 2008
44. Sood A, Sood R, Brinker F J., Mann R, Loehrer L L., Wahner-Roedler D L. Potential for interactions between dietary supplements and prescription medications. Am J Med 2008 121 3 207-211 (Pubitemid 351317929)
45. Wold R S., Lopez S T., Yau C L. et al. Increasing trends in elderly persons use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc 2005 105 1 54-63 (Pubitemid 40075492)
46. Peng C C., Glassman P A., Trilli L E., Hayes-Hunter J, Good C B. Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med 2004 164 6 630-636 (Pubitemid 38392977)
47. Bardia A, Nisly N L., Zimmerman M B., Gryzlak B M., Wallace R B. Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc 2007 82 5 561-566 (Pubitemid 46709424)
48. Gardiner P, Graham R, Legedza A T., Ahn A C., Eisenberg D M., Phillips R S. Factors associated with herbal therapy use by adults in the United States. Altern Ther Health Med 2007 13 2 22-29 (Pubitemid 46427629)
49. Kennedy J, Wang C C., Wu C H. Patient disclosure about herb and supplement use among adults in the US. Evid Based Complement Alternat Med 2008 5 4 451-456
50. Ang-Lee M K., Moss J, Yuan C S. Herbal medicines and perioperative care. JAMA 2001 286 2 208-216 (Pubitemid 32640852)
51. Kaye A D., Clarke R C., Sabar R et al. Herbal medicines: current trends in anesthesiology practicea hospital survey. J Clin Anesth 2000 12 6 468-471
52. Mehta D H., Phillips R S., Davis R B., McCarthy E P. Use of complementary and alternative therapies by Asian Americans. Results from the National Health Interview Survey. J Gen Intern Med 2007 22 6 762-767 (Pubitemid 46763972)
53. Strader D B., Bacon B R., Lindsay K L. et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002 97 9 2391-2397
54. Cohen M R. Herbal and complementary and alternative medicine therapies for liver disease. A focus on Chinese traditional medicine in hepatitis C virus. Clin Liver Dis 2001 5 2 461-478, vii (Pubitemid 32475750)
55. Chalasani N, Fontana R J., Bonkovsky H L. et al, Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008 135 6 1924-1934, 1934, e1e4
56. Bovill J G. Adverse drug interactions in anesthesia. J Clin Anesth 1997 9 6, Suppl 3S-13S